Mesbah Shams; Azar Sattarinezhad; Hossainali Rostamipour; Azar Purkhosrow; Elahe Sattarinezhad
Abstract
Introduction: Polycystic ovarian syndrome (PCOS) is one of the most common hormonal disorders affecting women of reproductive age. Numerous studies have suggested the involvement of inflammation in the pathogenesis of PCOS. As a result, drugs with anti-inflammatory effects may offer therapeutic benefits ...
Read More
Introduction: Polycystic ovarian syndrome (PCOS) is one of the most common hormonal disorders affecting women of reproductive age. Numerous studies have suggested the involvement of inflammation in the pathogenesis of PCOS. As a result, drugs with anti-inflammatory effects may offer therapeutic benefits for this condition. The standard medications used in treating PCOS include cyproterone compound (cyproterone acetate + ethinyl estradiol) combined with spironolactone, metformin, and pioglitazone. This study aimed to compare the effects of these drugs on the serum levels of inflammatory markers, including hs-CRP, C3, and C4, in women with PCOS.Materials and methodsNinety women with PCOS were randomly assigned to three treatment groups for 90 days as follows: Group CC-SP received cyproterone compound (cyproterone acetate 2 mg + ethinyl estradiol 35 µg) daily, along with 100 mg/day spironolactone; Group M received metformin (1500 mg/day); and Group P received pioglitazone (30 mg/day). Serum levels of hs-CRP, C3, and C4 were measured before and after treatment.Comparisons of changes in variables between groups were performed using the ANOVA test. Additionally, covariance (ANCOVA) analysis was used to examine differences between groups, adjusting for confounding variables. Probability values of ≤ 0.05 were considered statistically significant.ResultsThe C3, C4, and hs-CRP levels were increased in the CC-SP group while significantly decreased in the pioglitazone group (p<0.05). These changes were not statistically significant in the metformin group.ConclusionsPioglitazone reduces the serum levels of inflammatory markers and may be effectively combined with cyproterone and spironolactone in the treatment of PCOS.
Ava Hemmat; Faezeh Mashhadi; Mohsen Nematy; Nayere Khadem; Ezzat Hajmolla Rezaei; Fatemeh Roudi
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrinological disorder in women of reproductive age. Several studies have shown that inflammation factors have a crucial role in the function of the ovary as ovarian dysfunction can be caused by an imbalance of pro-inflammatory cytokines. Other studies ...
Read More
Polycystic ovary syndrome (PCOS) is the most common endocrinological disorder in women of reproductive age. Several studies have shown that inflammation factors have a crucial role in the function of the ovary as ovarian dysfunction can be caused by an imbalance of pro-inflammatory cytokines. Other studies have shown that PCOS patients have high levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), c-reactive protein (CRP(, interleukin-6 )IL-6(, and interleukin-8 (IL-8). Inflammation can be caused by a variety of factors including diet, and diet-induced inflammation can contribute to insulin resistance and atherogenesis as well as ovulation problems in women with PCOS. It is possible to calculate the components of diet and inflammation caused by diet using many different indices. The Healthy Eating Index (HEI) and Dietary Inflammatory Index (DII) are relatively new indices. As HEI is the overall health index for diet and DII indicates the inflammatory index of the diet, it is possible that a person’s diet can be generally healthy but has a high risk of inflammation, so these two indices should be considered together. Furthermore, dietary management of PCOS patients can reduce hyperinsulinemia, hyperandrogenism, and inflammation, which in turn helps to control and reduce disease complications such as infertility.